D Molecular Therapeutics, Inc.’s FDMT share price has dipped by 5.25%, which has investors questioning if this is right time to buy.

Gene therapy is just coming into the fore and that's a big area for Astellas,” Hardiman said. With economic forces favouring big pharma, one might be tempted to describe the current climate as a ...

One month ago, the FDA approved two gene therapies for sickle cell disease, including the first CRISPR drug to get the agency's nod. At the Informa Biotech Showcase on the outskirts of the JP ...